The source of “Starpharma’s DEP Irinotecan combination cancer drug has shown to be superior to Onivyde” comes from research and presentations by Starpharma itself.
They have reported on the anti-cancer activity of their DEP® irinotecan in human colon and pancreatic cancer xenograft models, highlighting its advantages over conventional treatments.
Specifically, DEP® irinotecan incorporates the active irinotecan derivative SN-38, which avoids the need for hepatic conversion and is expected to accumulate preferentially in tumor tissue, exerting a superior anti-tumor effect1. This data was presented at the American Association for Cancer Research (AACR) and further detailed in a poster showcasing DEP® irinotecan’s combination data with leading anticancer therapies.Onivyde® (irinotecan liposome injection) is a prescription medicine used to treat adults with pancreatic cancer that has spread to other parts of the body.
The comparison between Starpharma’s DEP Irinotecan and Onivyde seems to be based on the enhanced efficacy and delivery mechanism of Starpharma’s product. For more detailed information, you can refer to the research and publications by Starpharma.
